Investigational drug · Phase 2
BAY3283142
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Kidney Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
8
Any phase or sponsor naming "BAY3283142"
First trial start
2024
Aug 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAY3283142", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "BAY3283142" as an intervention, largest first.
- A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT06522997 · 1,222 participants · Start Aug 8, 2024 · Primary completion Oct 24, 2025
Drug: BAY3283142; Placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Chula Vista, California; San Dimas, California · 153 sites in all
- A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood PressureCompleted
BayerBayer (BAYRY)
NCT06428825 · 75 participants · Start Aug 16, 2024 · Primary completion Nov 21, 2025
Drug: BAY3283142; Placebo to BAY3283142 · For: Chronic Kidney Disease; Arterial Hypertension
Sites: Mannheim, Germany; Berlin, Germany
BayerBayer (BAYRY)
NCT05491642 · 56 participants · Start Sep 8, 2022 · Primary completion Jan 3, 2023
Drug: BAY3283142; Placebo to BAY3283142 · For: Chronic Kidney Disease; Hypertension
Sites: Sofia, Bulgaria; Mannheim, Germany; Berlin, Germany · 4 sites in all
BayerBayer (BAYRY)
NCT05515432 · 45 participants · Start Aug 11, 2022 · Primary completion Mar 7, 2023
Drug: Single oral dose of BAY3283142 IR (immediate release) tablet · For: Chronic Kidney Disease; Renal Impairment; Healthy Volunteers
Sites: Kiel, Germany
BayerBayer (BAYRY)
NCT06402721 · 24 participants · Start May 17, 2024 · Primary completion Feb 24, 2025
Drug: BAY3283142 · For: Chronic Kidney Disease; Hepatic Impairment
Sites: Orlando, Florida
BayerBayer (BAYRY)
NCT05800444 · 24 participants · Start Apr 3, 2023 · Primary completion Jul 19, 2023
Drug: BAY3283142 · For: Chronic Kidney Disease; Healthy Volunteers
Sites: Fukuoka, Japan
BayerBayer (BAYRY)
NCT06487845 · 24 participants · Start Jul 4, 2024 · Primary completion Sep 19, 2024
Drug: BAY3283142; Placebo · For: Chronic Kidney Disease; Non-proliferative Diabetic Retinopathy; Healthy Volunteers
Sites: Guangzhou, China
BayerBayer (BAYRY)
NCT07722585 · 16 participants · Start Jul 28, 2026 · Primary completion Oct 12, 2026
Drug: Nurandociguat (BAY3283142) old tablet - SD; Nurandociguat (BAY3283142) new tablet - SD and 2 more · For: Chronic Kidney Disease
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bayer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.